Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
neuropsychiatrie
Erschienen in:

04.06.2024 | Typ-1-Diabetes | review

The relationship between schizophrenia or schizoaffective disorder and type 1 diabetes mellitus: a scoping review of observational studies

verfasst von: Yi-Chun Liu, Yin-To Liao, Kuan-Han Lin

Erschienen in: neuropsychiatrie | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Summary

Objective

Both schizophrenia and type 1 diabetes mellitus (T1D) are known as immune-related disorders. We systematically reviewed observational studies to explore the relationship between schizophrenia or schizoaffective disorder and T1D.

Methods

A preliminary search of articles was completed using the following databases: Airiti Library, CINAHL Complete (via EBSCOhost), OVID MEDLINE, Embase, and PubMed. Two researchers independently assessed each study’s quality based on Joanna Briggs Institute (JBI). A narrative review summarized the potential relationship between the two diseases.

Results

Eleven studies were included in the final analysis. Six observational studies investigated the risk of schizophrenia and schizoaffective disorder in patients with T1D. Two studies showed negative correlations, one showed no correlation, and three showed positive correlations. On the other hand, five studies reported the prevalence of T1D in patients with schizophrenia. Two of them showed positive associations, and three others showed no association. Although the majority of the included studies suggested a positive association between the two medical conditions, these studies were still too heterogeneous to draw consistent results.

Conclusion

We found conflicting results regarding the bidirectional relationship between schizophrenia or schizoaffective disorder and T1D. These may stem from differences in study design, sampling methods, or definition of diagnoses, which are essential aspects to consider in future research.
Nächster Artikel Relationship of sleep quality, chronotype, and obstructive sleep apnea with migraine in the elderly population
Literatur
1.
2.
Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV. Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin Psychiatry. 1999;60:874–82.PubMedCrossRef
3.
Harvey PD, Heaton RK, Carpenter WT Jr., Green MF, Gold JM, Schoenbaum M. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res. 2012;140:1–8.PubMedPubMedCentralCrossRef
4.
Cotton SM, Lambert M, Schimmelmann BG, Mackinnon A, Gleeson JFM, Berk M, Hides L, Chanen AM, Scott J, Schottle D, McGorry PD, Conus P. Differences between first episode schizophrenia and schizoaffective disorder. Schizophr Res. 2013;147:169–74.PubMedCrossRef
5.
Amann BL, Canales-Rodriguez EJ, Madre M, Radua J, Monte G, Alonso-Lana S, Landin-Romero R, Moreno-Alcazar A, Bonnin CM, Sarro S, Ortiz-Gil J, Gomar JJ, Moro N, Fernandez-Corcuera P, Goikolea JM, Blanch J, Salvador R, Vieta E, McKenna PJ, Pomarol-Clotet E. Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2016;133:23–33.PubMedCrossRef
6.
Ivleva EI, Bidesi AS, Keshavan MS, Pearlson GD, Meda SA, Dodig D, Moates AF, Lu H, Francis AN, Tandon N, Schretlen DJ, Sweeney JA, Clementz BA, Tamminga CA. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry. 2013;170:1285–96.PubMedPubMedCentralCrossRef
7.
Walther S, Lefebvre S, Conring F, Gangl N, Nadesalingam N, Alexaki D, Wuthrich F, Ruter M, Viher PV, Federspiel A, Wiest R, Stegmayer K. Limbic links to paranoia: increased resting-state functional connectivity between amygdala, hippocampus and orbitofrontal cortex in schizophrenia patients with paranoia. Eur Arch Psychiatry Clin Neurosci. 2022;272:1021–32.PubMedCrossRef
8.
Nawaz R, Gul S, Amin R, Huma T, Al Mughairbi F. Overview of schizophrenia research and treatment in Pakistan. Heliyon. 2020;6:e5545.PubMedPubMedCentralCrossRef
9.
Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study. Schizophr Bull. 2016;2018(44):1195–203.
10.
Wildgust HJ, Hodgson R, Beary M. The paradox of premature mortality in schizophrenia: new research questions. J Psychopharmacol. 2010;24:9–15.PubMedPubMedCentralCrossRef
11.
Wildgust HJ, Beary M. Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol. 2010;24:37–50.PubMedPubMedCentralCrossRef
12.
van Mierlo HC, Schot A, Boks MPM, de Witte LD. The association between schizophrenia and the immune system: Review of the evidence from unbiased ‘omic-studies. Schizophr Res. 2020;217:114–23.PubMedCrossRef
13.
Dietert RR. Role of developmental immunotoxicity and immune dysfunction in chronic disease and cancer. Reprod Toxicol. 2011;31:319–26.PubMedCrossRef
14.
Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150:245–51.PubMedCrossRef
15.
Tiosano S, Farhi A, Watad A, Grysman N, Stryjer R, Amital H, Comaneshter D, Cohen AD, Amital D. Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study. Epidemiol Psychiatr Sci. 2017;26:424–9.PubMedCrossRef
16.
Oken RJ, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull. 1999;25:625–38.PubMedCrossRef
17.
Juvonen H, Reunanen A, Haukka J, Muhonen M, Suvisaari J, Arajarvi R, Partonen T, Lonnqvist J. Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Arch Gen Psychiatry. 2007;64:894–9.PubMedCrossRef
18.
Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, Murray RM, McGuire P, Mondelli V. Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. Biol Psychiatry. 2019;85:35–48.PubMedPubMedCentralCrossRef
19.
Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res. 1992;6:181–92.PubMedCrossRef
20.
Vinogradov S, Gottesman MHW II, Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull. 1991;17:669–78.PubMedCrossRef
21.
Bending D, Zaccone P, Cooke A. Inflammation and type one diabetes. Int Immunol. 2012;24:339–46.PubMedCrossRef
22.
23.
Whittemore R, Jaser S, Chao A, Jang M, Grey M. Psychological experience of parents of children with type 1 diabetes: a systematic mixed-studies review. Diabetes Educ. 2012;38:562–79.PubMedPubMedCentralCrossRef
24.
Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–54.PubMedPubMedCentralCrossRef
25.
Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26:1052–7.PubMedCrossRef
26.
Delamater AM, Jacobson AM, Anderson B, Cox D, Fisher L, Lustman P, Rubin R, Wysocki T. Psychosocial therapies in diabetes: report of the Psychosocial Therapies Working Group. Diabetes Care. 2001;24:1286–92.PubMedCrossRef
27.
Vaseghi H, Jadali Z. Th1/Th2 cytokines in Type 1 diabetes: Relation to duration of disease and gender. Indian J Endocrinol Metab. 2016;20:312–6.PubMedPubMedCentralCrossRef
28.
Avgustin B, Wraber B, Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J. 2005;46:268–74.PubMed
29.
Na KS, Kim YK. Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology. 2007;56:55–63.PubMedCrossRef
30.
Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X. Th17 cells in type 1 diabetes. Cell Immunol. 2012;280:16–21.PubMedCrossRef
31.
Debnath M, Berk M. Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull. 2014;40:1412–21.PubMedPubMedCentralCrossRef
32.
Subbanna M, Shivakumar V, Bhalerao G, Varambally S, Venkatasubramanian G, Debnath M. Variants of Th17 pathway-related genes influence brain morphometric changes and the risk of schizophrenia through epistatic interactions. Psychiatr Genet. 2022;32:146–55.PubMedCrossRef
33.
Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, Vives-Pi M, Powrie J, Tree T, Marchetti P, Huang GC, Gurzov EN, Pujol-Borrell R, Eizirik DL, Peakman M. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes. 2011;60:2112–9.PubMedPubMedCentralCrossRef
34.
Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol. 2009;39:216–24.PubMedPubMedCentralCrossRef
35.
36.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Genetic R, Outcome in P, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA. Common variants conferring risk of schizophrenia. Nature. 2009;460:744–747.
37.
Stringer S, Kahn RS, de Witte LD, Ophoff RA, Derks EM. Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr Res. 2014;159:347–52.PubMedCrossRef
38.
Chen MH, Tsai SJ, Bai YM, Huang KL, Su TP, Chen TJ, Hsu JW. Type 1 diabetes mellitus and risks of major psychiatric disorders: A nationwide population-based cohort study. Diabetes Metab. 2022;48:101319.PubMedCrossRef
39.
Melkersson K. Schizophrenia- or schizoaffective disorder diagnosis and the risk for subsequent type 1- or type 2 diabetes mellitus: a Swedish nationwide register-based cohort study. Neuro Endocrinol Lett. 2020;41:245–54.PubMed
40.
Melkersson K, Wernroth ML. Type 1 diabetes mellitus and the risk for schizophrenia or schizoaffective disorder: a Swedish nationwide register-based cohort study. Neuro Endocrinol Lett. 2019;40:125–34.PubMed
41.
Cooper MN, Lin A, Alvares GA, de Klerk NH, Jones TW, Davis EA. Psychiatric disorders during early adulthood in those with childhood onset type 1 diabetes: Rates and clinical risk factors from population-based follow-up. Pediatr Diabetes. 2017;18:599–606.PubMedCrossRef
42.
Cremaschi L, Kardell M, Johansson V, Isgren A, Sellgren CM, Altamura AC, Hultman CM, Landen M. Prevalences of autoimmune diseases in schizophrenia, bipolar I and II disorder, and controls. Psychiatry Res. 2017;258:9–14.PubMedCrossRef
43.
Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci. 2014;264:3–28.PubMedCrossRef
44.
Chen SJ, Chao YL, Chen CY, Chang CM, Wu EC, Wu CS, Yeh HH, Chen CH, Tsai HJ. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br J Psychiatry. 2012;200:374–80.PubMedCrossRef
45.
Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12:638–46.PubMedPubMedCentralCrossRef
46.
Basina M, Maahs DM. Age at type 1 diabetes onset: a new risk factor and call for focused treatment. Lancet. 2018;392:453–4.PubMedCrossRef
47.
Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, Shin IJ, Kirkbride JB, Jones P, Kim JH, Kim JY, Carvalho AF, Seeman MV, Correll CU, Fusar-Poli P. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27:281–95.PubMedCrossRef
48.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(W264):264–9.PubMedCrossRef
49.
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodol Qual Case Ser Studies: Introd To Jbi Crit Apprais Tool Jbi Evid Synth. 2020;18:2127–33.
50.
Kuraeiad S, Kotepui KU, Masangkay FR, Mahittikorn A, Kotepui M. Association of uric acid levels with severity of Plasmodium infections: a systematic review and meta-analysis. Sci Rep. 2023;13:14979.PubMedPubMedCentralCrossRef
51.
Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011;168:1303–10.PubMedCrossRef
52.
Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163:521–8.PubMedCrossRef
53.
Corbeil O, Essiambre AM, Bechard L, Roy AA, Huot-Lavoie M, Brodeur S, Chandrasena R, Theriault C, Crocker C, Melun JP, Tibbo P, Demers MF, Roy MA. Real-life effectiveness of transitioning from paliperidone palmitate 1‑monthly to paliperidone palmitate 3‑monthly long-acting injectable formulation. Ther Adv Psychopharmacol. 2022;12:20451253221136021.PubMedPubMedCentralCrossRef
54.
Hallford P, Clair DS, Halley L, Mustard C, Wei J. A study of type‑1 diabetes associated autoantibodies in schizophrenia. Schizophr Res. 2016;176:186–90.PubMedCrossRef
55.
Starosz A, Jamiolkowska-Sztabkowska M, Glowinska-Olszewska B, Moniuszko M, Bossowski A, Grubczak K. Immunological balance between Treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children. Front Immunol. 2022;13:958430.PubMedPubMedCentralCrossRef
56.
Liu X, Nudel R, Thompson WK, Appadurai V, Schork AJ, Buil A, Rasmussen S, Allesoe RL, Werge T, Mors O, Borglum AD, Hougaard DM, Mortensen PB, Nordentoft M, Benros ME. Genetic factors underlying the bidirectional relationship between autoimmune and mental disorders—Findings from a Danish population-based study. Brain Behav Immun. 2021;91:10–23.PubMedCrossRef
57.
Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf. 2017;40:771–81.PubMedCrossRef
58.
Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics. 2013;6 Suppl 1:S17.
59.
Fanelli G, Franke B, De Witte W, Ruisch IH, Haavik J, van Gils V, Jansen WJ, Vos SJB, Lind L, Buitelaar JK, Banaschewski T, Dalsgaard S, Serretti A, Mota NR, Poelmans G, Bralten J. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. Transl Psychiatry. 2022;12:59.PubMedPubMedCentralCrossRef
Metadaten
Titel
The relationship between schizophrenia or schizoaffective disorder and type 1 diabetes mellitus: a scoping review of observational studies
verfasst von
Yi-Chun Liu
Yin-To Liao
Kuan-Han Lin
Publikationsdatum
04.06.2024
Verlag
Springer Vienna
Erschienen in
neuropsychiatrie / Ausgabe 4/2024
Print ISSN: 0948-6259
Elektronische ISSN: 2194-1327
DOI
https://doi.org/10.1007/s40211-024-00499-y

Weitere Artikel der Ausgabe 4/2024

bericht aus dem ögpp-vorstand

  • bericht aus dem ögpp-vorstand

kultur im kontext

  • kultur im kontext

Bericht aus dem Vorstand der ÖGKJP

  • bericht aus dem ögkjp-vorstand

Relationship of sleep quality, chronotype, and obstructive sleep apnea with migraine in the elderly population

  • original article

On the rise or a return to pre-pandemic levels? A cross-sectional online survey on nicotine, alcohol, and illicit drug use among youth

Associations of attention-deficit/hyperactivity disorder with inflammatory diseases. Results from the nationwide German Health Interview and Examination Survey for Children and Adolescents (KiGGS)

  • Open Access
  • original article
Bildnachweise